Hubertus von Baumbach has been Chairman of the Board of Managing Directors of Boehringer Ingelheim since July 2016. Prior to being appointed Chairman of the Board, Mr. von Baumbach served as Chief Financial Officer since 2009 and previously held multiple leadership positions within Boehringer Ingelheim. He started his professional career in 1998 in the US affiliate of F. Hoffmann-La Roche AG in Nutley, New Jersey. Mr. von Baumbach was trained as a bank clerk at Merck, Finck & Co. in Munich, received his law degree from the Ludwig-Maximilians-Universität in Munich, took the German Bar Exam, and received a MBA from Sloan School of Management at Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. Mr. von Baumbach serves as a Member on Boards and Advisory Boards of both national and international industry associations as well as not-for-profit organizations. Boehringer Ingelheim, an independent and family-owned company founded in 1885, develops, produces, and distributes innovative medicines for humans and animals. Not being listed, gives Boehringer Ingelheim the freedom to pursue a long-term vision to medicine, looking ahead to identify the health challenges of the future. Its mission is to create breakthrough therapies where the medical need is high, thus transforming lives for generations.
